Browsing by Author "Besbas, Nesrin"

Now showing 1 - 3 of 3

Follow-Up Results of Patients with ADCK4 Mutations and the Efficacy of Coq10 Treatment
(2017) Atmaca, Mustafa; Gulhan, Bora; Korkmaz, Emine; Inozu, Mihriban; Soylemezoglu, Oguz; Candan, Cengiz; Bayazit, Aysun Karabay; Elmaci, Ahmet Midhat; Parmaksiz, Gonul; Duzova, Ali; Besbas, Nesrin; Topaloglu, Rezan; Ozaltin, Fatih; https://orcid.org/0000-0003-2373-1837; 28337616; AAM-2935-2021
ADCK4-related glomerulopathy is an important differential diagnosis in adolescents with steroid-resistant nephrotic syndrome (SRNS) and/or chronic kidney disease (CKD) of unknown origin. We screened adolescent patients to determine the frequency of ADCK4 mutation and the efficacy of early CoQ10 administration. A total of 146 index patients aged 10-18 years, with newly diagnosed non-nephrotic proteinuria, nephrotic syndrome, or chronic renal failure and end-stage kidney disease (ESKD) of unknown etiology were screened for ADCK4 mutation. Twenty-eight individuals with bi-allelic mutation from 11 families were identified. Median age at diagnosis was 12.4 (interquartile range [IQR] 8.04-19.7) years. Upon first admission, all patients had albuminuria and 18 had CKD (6 ESKD). Eight were diagnosed either through the screening of family members following index case identification or during genetic investigation of proteinuria in an individual with a history of a transplanted sibling. Median age of these 8 patients was 21.5 (range 4.4-39) years. CoQ10 supplementation was administered following genetic diagnosis. Median estimated glomerular filtration rate (eGFR) just before CoQ10 administration was 140 (IQR 117-155) ml/min/1.73m(2), proteinuria was 1,008 (IQR 281-1,567) mg/m(2)/day. After a median follow-up of 11.5 (range 4-21) months following CoQ10 administration, proteinuria was significantly decreased (median 363 [IQR 175-561] mg/m(2)/day, P=0.025), whereas eGFR was preserved (median 137 [IQR 113-158] ml/min/1.73m(2), P=0.61). ADCK4 mutations are one of the most common causes of adolescent-onset albuminuria and/or CKD of unknown etiology in Turkey. CoQ10 supplementation appears efficacious at reducing proteinuria, and may thereby be renoprotective.
Results of Turkish Multicentric National Cystinosis Registry
(2015) Topaloglu, Rezan; Gulhan, Bora; Ozaltin, Fatih; Bodur, Ilknur; Besbas, Nesrin; Dursun, Hasan; Yilmaz, Alev; Gurgoze, Metin Kaya; Gokce, Ibrahim; Akinci, Nurver; Erdogan, Ozlem; Dursun, Ismail; Canpolat, Nur; Donmez, Osman; Cayci, Fatma Semsa; Serdaroglu, Erkin; Comak, Elif; Nalcacioglu, Hulya; Gok, Faysal; Yuksel, Selcuk; Soylu, Alper; Bahat, Elif; Hacihamdioglu, Duygu Ovunc; Candan, Cengiz; Bastug, Funda; AAW-8783-2020
Sinus Tachycardia Related To Tacrolimus After Kidney Transplantation in Children and Young Adults
(2015) Erdogan, Ilkay; Bilginer, Yelda; Duzova, Ali; Besbas, Nesrin; 0000-0001-6887-3033; 0000-0002-4365-2995; 27735797; ABB-2220-2021; AAB-7679-2021; AAB-7692-2021; AAJ-2305-2021
Tacrolimus is a potent immunosuppressive agent widely used after organ transplantation. In this present study we present eight patients who complained of palpitation after kidney transplantation. Eight out of 31 patients who received tacrolimus after kidney transplantation suffered from tachycardia. Resting electrocardiography, 24 hours Holter monitorization, echocardiography were performed, and serum levels of cardiac troponin T, creatine kinase, CKMB, brain natriuretic peptide and tacrolimus were measured. The median time to palpitation after kidney transplantation was 30 days in seven patients, and one patient complained of palpitation five years after transplantation. Cardiovascular assessment revealed sinus tachycardia in all patients. Beta-blocker was instituted in five patients. After two months all patients were asymptomatic and their pulse rates were within normal limits. Transient sinus tachycardia is a frequent adverse event during tacrolimus therapy in children and young adults, at therapeutic levels. Patients may benefit from beta-blockers.